Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Ritika has also extensively worked with clients such as WHO, GAVI Alliance, USAID, Gilead, Novartis, Sanofi Pasteur
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research
Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorised in the US to prevent Covid-19
It plans to double its network to 50 centres across India in the next three years
The country’s vaccine production has more than doubled since April and is set to touch 300 million doses next month
The vaccine was 85 percent effective in preventing severe disease across all regions.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)